Zoetis Inc
NYSE:ZTS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
145.54
199.94
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Zoetis Inc
Zoetis Inc
Cash Equivalents
Zoetis Inc
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Zoetis Inc
NYSE:ZTS
|
Cash Equivalents
$1.7B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
11%
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash Equivalents
$4.8B
|
CAGR 3-Years
32%
|
CAGR 5-Years
27%
|
CAGR 10-Years
-10%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash Equivalents
$7.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
5%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash Equivalents
$1.1B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-8%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash Equivalents
$14.6B
|
CAGR 3-Years
13%
|
CAGR 5-Years
13%
|
CAGR 10-Years
3%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash Equivalents
$3.4B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
17%
|
CAGR 10-Years
1%
|
|
Zoetis Inc
Glance View
In the vast panorama of the global animal health industry, Zoetis Inc. emerges as a formidable player, intricately weaving a narrative of innovation and growth. Originally part of Pfizer, Zoetis embarked on its solo journey in 2013, driven by a singular mission to understand, anticipate, and amplify the needs of both livestock and companion animals. At the heart of its operations lies an impressive pipeline of products—from vaccines and diagnostics to genetic tests and precision livestock farming software—designed to improve the health of animals. Its comprehensive approach ensures not only the well-being of the animals but also supports the burgeoning needs of veterinary practitioners and livestock producers worldwide. Financially, Zoetis masters the art of monetizing its deep-rooted expertise in animal biology and science. Revenue streams flow predominantly from the sale of these innovative products, with livestock and companion animal segments each contributing significant streams of income. The company capitalizes on its extensive global footprint, reaching customers in over 100 countries, ensuring diversified and steady cash flows. Its continued investment in R&D underscores a long-term commitment to innovation, enhancing its product offerings and driving future growth. In a world increasingly conscious of the importance of animal welfare and food security, Zoetis stands at a strategic intersection, aligning its business model with the evolving dynamics of both consumer preferences and regulatory landscapes.
See Also
What is Zoetis Inc's Cash Equivalents?
Cash Equivalents
1.7B
USD
Based on the financial report for Sep 30, 2024, Zoetis Inc's Cash Equivalents amounts to 1.7B USD.
What is Zoetis Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
11%
Over the last year, the Cash Equivalents growth was -2%. The average annual Cash Equivalents growth rates for Zoetis Inc have been -19% over the past three years , -1% over the past five years , and 11% over the past ten years .
You don't have any saved screeners yet
